Traditional antibody optimization approaches often result in drug candidates with suboptimal binding affinity, developability or immunogenicity.
In this technical poster we show that deep contextual LLMs trained on high-throughput affinity data can quantitatively predict binding of unseen antibody sequence variants, along with associated measures for optimizing drug developability and immunogenicity.
Download the poster for more details.